Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
| Property | Value | Notes |
|---|---|---|
| 化学分类 | 线性肽 | 由28个氨基酸组成 |
| 分子量 | 约3108 Da | 合成版本一致 |
| 外观 | 白色至类白色粉末 | 冻干品 |
| 溶解度 | 易溶于水 | 微溶于有机溶剂 |
| 储存温度 | -20°C（冻干） | 溶解后2-8°C |
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Lyophilized thymosin alpha 1 is typically stored refrigerated at 2 to 8 degrees Celsius and kept away from light. Reconstituted solutions are less stable and are usually used promptly after preparation. Repeated freeze-thaw cycles are avoided because they can promote aggregation and loss of activity. The peptide adsorbs to some plastic and glass surfaces, so a carrier protein is often added to dilute working solutions. Manufacturer instructions and published protocols both govern handling.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Anne Ephrussi studied biology at Harvard University in the Department of Biochemistry and Molecular Biology from where she graduated in 1979. She continued to do her PhD at the Massachusetts Institute of Technology (MIT) in the group of Susumu Tonegawa where she received her doctoral degree in 1985. Ephrussi performed postdoctoral research at Harvard University in the lab of Thomas Maniatis from 1986 to 1989 and at the Whitehead Institute for Biomedical Research with Ruth Lehmann from 1989 to 1992. Since 1992, Anne Ephrussi has been a group leader at the European Molecular Biology Laboratory (EMBL). She became the head of EMBL International Centre for Advanced Training in 2005. She served as Associate Dean (1999 - 2005) and Dean (2005 - 2008) of Graduate Studies of the EMBL International PhD program and as head of the developmental biology unit (2007-2021). She is part of numerous international Scientific Advisory Boards and Panels, organizes international conferences and scientific meetings and evaluates research grant and fellowship applications for a variety of renowned funding bodies.
Two different kinds of blank may be measured: a sample of dead carbon that has undergone no chemical processing, to detect any machine background, and a sample known as a process blank made from dead carbon that is processed into target material in exactly the same way as the sample which is being dated. Any 14C signal from the machine background blank is likely to be caused either by beams of ions that have not followed the expected path inside the detector or by carbon hydrides such as 12CH2 or 13CH. A 14C signal from the process blank measures the amount of contamination introduced during the preparation of the sample. These measurements are used in the subsequent calculation of the age of the sample.
Stanley Whittingham conceived intercalation electrodes in the 1970s and created the first rechargeable lithium-ion battery, based on a titanium disulfide cathode and a lithium-aluminium anode, although it suffered from safety problems and was never commercialized. John Goodenough expanded on this work in 1980 by using lithium cobalt oxide as a cathode. The first prototype of the modern Li-ion battery, which uses a carbonaceous anode rather than lithium metal, was developed by Akira Yoshino in 1985 and commercialized by a Sony and Asahi Kasei team led by Yoshio Nishi in 1991. Whittingham, Goodenough, and Yoshino were awarded the 2019 Nobel Prize in Chemistry for their contributions to the development of lithium-ion batteries. Lithium-ion batteries can be a fire or explosion hazard as they contain flammable electrolytes. Progress has been made in the development and manufacturing of safer lithium-ion batteries. Lithium-ion solid-state batteries are being developed to eliminate the flammable electrolyte. Lithium and other minerals can have significant issues in mining, with lithium being water intensive in often arid regions and other minerals used in some Li-ion chemistries potentially being conflict minerals such as cobalt. Environmental issues have encouraged some researchers to improve mineral efficiency and find alternatives such as lithium iron phosphate lithium-ion chemistries or non-lithium-based battery chemistries such as sodium-ion and iron-air batteries. Lithium-ion cells can be manufactured to optimize energy density or power density.
In the Bronze Age, the Hellenes had trade and cultural contacts with Egypt. Before the time that Alexander the Great occupied Egypt, the Greek name, sphinx, was already applied to these statues. The historians and geographers of Greece such as Herodotus wrote extensively about Egyptian culture. There was a single sphinx in Greek mythology, a unique demon of destruction and bad luck. Apollodorus describes the sphinx as having a woman's face, the body and tail of a lion and the wings of a bird. Pliny the Elder mentions that Ethiopia produces plenty of sphinxes, with brown hair and breasts, corroborated by 20th-century archeologists. Statius describes her as a winged monster, with pallid cheeks, eyes tainted with corruption, plumes clotted with gore and talons on livid hands. John Tzetzes described her as having the front of a lion, the rear of a human, the wings of a griffin and the claws of an eagle. Sometimes, the wings are specified to be those of an eagle, and the tail to be serpent-headed. According to Hesiod, the Sphinx was a daughter of Orthrus and an unknown she—either the Chimera, Echidna, or Ceto. According to Apollodorus and Lasus, she was a daughter of Echidna and Typhon. The sphinx was the emblem of the ancient city-state of Chios, and appeared on seals and the obverse side of coins from the 6th century BC until the 3rd century AD.
The suspensory muscle of duodenum (also known as suspensory ligament of duodenum, Treitz's muscle or ligament of Treitz) is a thin muscle connecting the junction between the duodenum and jejunum (the small intestine's first and second parts, respectively), as well as the duodenojejunal flexure to connective tissue surrounding the superior mesenteric and coeliac arteries. The suspensory muscle most often connects to both the third and fourth parts of the duodenum, as well as the duodenojejunal flexure, although the attachment is quite variable. The suspensory muscle marks the formal division between the duodenum and the jejunum. This division is used to mark the difference between the upper and lower gastrointestinal tracts, which is relevant in clinical medicine as it may determine the source of gastrointestinal bleeding. The suspensory muscle is derived from mesoderm and plays a role in the embryological rotation of the gut, by offering a point of fixation for the rotating gut. It is also thought to help digestion by widening the angle of the duodenojejunal flexure. Superior mesenteric artery syndrome is a rare abnormality caused by a congenitally short suspensory muscle.
Sources: en.wikipedia.org
With phosphorus(V)sulfide, vinylene carbonate reacts to the corresponding vinylenethionocarbonate (2-thiono-1,3-dioxol-4-ene), which gives ketene in quantitative yield upon UV irradiation. The reaction is a good alternative to the decomposition of α-diazoketones.
== Legal and judicial figures == Richard Harison (1764), first U.S. attorney for the District of New York Peter van Schaack (1767), loyalist and attorney Abraham Van Vechten (1780s), two-time New York attorney general Anthony Bleecker (1791), lawyer and founding member of the New-York Historical Society Samuel Jones Jr. (1793), recorder of New York City; chancellor of New York; chief justice of the New York City Superior Court Augustus B. Woodward (1793), first chief justice of the Michigan Territory; one of the founders of the University of Michigan Thomas Phoenix (1795), New York County district attorney Pierre C. Van Wyck (1795), New York County district attorney; recorder of New York City William P. Van Ness (1797), judge on the United States District Court for the Southern District of New York Sampson Simson (1800), attorney, philanthropist, remembered as the "father of Mount Sinai Hospital" Alexander Hamilton Jr. (1804), son of Alexander Hamilton, attorney, soldier, and member of the New York State Assembly Hugh Maxwell (1808), New York County district attorney and Collector of the Port of New York Matthew C. Paterson (1809), New York County district attorney Ogden Hoffman (1812), former New York State attorney general, U.S. attorney for the Southern District of New York, and U.S. congressman from New York Frederic de Peyster (1819), New York attorney Theodore Sedgwick III (1829), U.S. attorney for the Southern District of New York Samuel Blatchford (1837), associate justice of the U.S.
== International accreditation == In 2007, Haim Hacham et al. published a paper addressing the need for and the process of international standardised accreditation for laboratory proficiency in Israel. With similar efforts, both the Japan Accreditation Board for Conformity Assessment (JAB) and the European Communities Confederation of Clinical Chemistry and Laboratory Medicine (EC4) have validated and convened ISO 15189 Medical laboratories — Requirements for quality and competence, respectively. In 2006, Spitzenberger and Edelhäuser expressed concerns that ISO accreditation may include obstacles arising from new emerging medical devices and the new approach of assessment; in so doing, they indicate the time dependence of standards.
== Pharmacology == Considered a low-to-medium-potency opioid, tilidine has the oral potency of about 0.2, that is, a dose of 100mg p.o. is equianalgesic to approximately 20mg morphine sulfate orally. It is administered orally (by mouth), rectally (by a suppository), or by injection (SC, IM, or slowly IV). Tilidine itself is only a weak opioid, but is rapidly metabolized in the liver and gut to its active metabolite nortilidine and then to bisnortilidine. It is the (1S,2R)-isomer (dextilidine) that is responsible for its analgesic activity. Nortilidine binds to opiate receptors in the central and peripheral nervous systems and suppresses pain perception and transmission. To purportedly counteract the abuse potential, tilidine is used in combination with the opioid receptor antagonist naloxone. The mixing ratio with naloxone is chosen so that the analgesic effect of tilidine is not impaired.
Sources: en.wikipedia.org
它不是经典的内分泌激素，而是一种免疫调节肽。其作用主要通过局部免疫细胞间的信号传递实现，而非经血液循环作用于远隔器官。
天然胸腺素α1主要从胸腺组织提取，也可在脾脏和淋巴结中检出。目前研究和临床使用的多为化学合成版本，不再依赖动物组织。
胸腺素组分5是牛胸腺提取物的粗组分，包含多种肽。胸腺素α1是其中一种被纯化和表征的单一肽，具有明确的28个氨基酸序列。
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.